Patents by Inventor Flavia Borellini

Flavia Borellini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Publication number: 20210369709
    Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Inventors: Yuri RUKAZENKOV, Serban GHIORGHIU, Flavia BORELLINI, Helen MANN
  • Cytokine-expressing cellular vaccines for treatment of prostate cancer
    Publication number: 20060057127
    Abstract: Genetically modified cytokine-expressing cells for use as vaccines in the treatment of prostate cancer are provided. More specifically, genetically modified, GM-CSF expressing cells as a means to generate an enhanced immune response to beta filamin and the use thereof in the treatment of prostate cancer are described.
    Type: Application
    Filed: September 10, 2004
    Publication date: March 16, 2006
    Inventors: Pocheng Liu, Kuoting Wu, Johanna Sy, Flavia Borellini
  • Quantitative assay of host cell DNA in a sample
    Patent number: 6864053
    Abstract: Detection of members of a conserved, dispersed gene family is used to ascertain levels of host cell genomic DNA in a sample.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: March 8, 2005
    Assignee: Cell Genesys
    Inventors: John M. Irving, Kenneth Ho, Michael Mok, Flavia Borellini
  • Carcinogen assay
    Patent number: 6593084
    Abstract: The present invention is drawn to methods and assays for the early determination of whether a test agent is a carcinogen. These novel methods and assays are used to correlate the pattern of differential gene expression from mammalian cells treated with the test agent with reference patterns of differential gene expression of mammalian cells treated with known carcinogens. Further, the present invention is drawn to methods of use of DNA and RNA isolated from the treated mammalian cells as well as kits comprising same. The present invention also is drawn to methods of determining whether a test agent is a carcinogen by measuring protein synthesis or post-translational modifications from mammalian cells treated with the test agent compared with mammalian cells treated with a known carcinogen.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: July 15, 2003
    Inventors: Robert Earl Bird, Oleg K. Glebov, Flavia Borellini, David Jacobson-Kram, Jeffrey M. Ostrove
  • CARCINOGEN ASSAY
    Publication number: 20020086288
    Abstract: The present invention is drawn to methods and assays for the early determination of whether a test agent is a carcinogen. These novel methods and assays are used to correlate the pattern of differential gene expression from mammalian cells treated with the test agent with reference patterns of differential gene expression of mammalian cells treated with known carcinogens. Further, the present invention is drawn to methods of use of DNA and RNA isolated from the treated mammalian cells as well as kits comprising same. The present invention also is drawn to methods of determining whether a test agent is a carcinogen by measuring protein synthesis or post-translational modifications from mammalian cells treated with the test agent compared with mammalian cells treated with a known carcinogen.
    Type: Application
    Filed: October 13, 1998
    Publication date: July 4, 2002
    Inventors: ROBERT EARL BIRD, OLEG K. GLEBOV, FLAVIA BORELLINI, DAVID JACOBSON-KRAM, JEFFREY M. OSTROVE